UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 3,984 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 13.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,194 shares of the company’s stock after selling 3,984 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Janux Therapeutics were worth $1,190,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $29,000. Amalgamated Bank boosted its stake in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares in the last quarter. Plato Investment Management Ltd bought a new stake in shares of Janux Therapeutics in the 2nd quarter worth about $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Janux Therapeutics during the 2nd quarter valued at about $151,000. 75.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The stock was bought at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now owns 9,317,246 shares of the company’s stock, valued at $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO David Alan Campbell sold 15,000 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the completion of the sale, the chief executive officer now owns 242,054 shares in the company, valued at $16,217,618. This represents a 5.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 192,032 shares of company stock valued at $9,512,515 in the last 90 days. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Trading Down 3.2 %

Shares of NASDAQ:JANX opened at $59.61 on Wednesday. The stock has a market capitalization of $3.13 billion, a P/E ratio of -50.95 and a beta of 3.29. Janux Therapeutics, Inc. has a 1-year low of $7.79 and a 1-year high of $71.71. The business has a 50-day moving average price of $53.37 and a two-hundred day moving average price of $46.92.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The business’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, equities analysts predict that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. UBS Group initiated coverage on Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target for the company. HC Wainwright boosted their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, BTIG Research upped their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.